The Icahn School of Medicine at Mount Sinai (ISMMS) was awarded a $507,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to study the role of exosomes in promoting prostate cancer metastasis and resistance to androgen deprivation therapy. The award period runs from June 15, 2024, to June 14, 2026. This federal grant supports innovative biomedical research focused on advancing understanding of the underlying mechanisms of prostate cancer progression and treatment resistance, which has important implications for improving healthcare outcomes for military service members and the broader population. As a renowned academic medical center, ISMMS has extensive expertise in translational research and collaborates with other leading institutions on federally-funded projects covering a wide range of medical disciplines.
Generated 2/25/25, 5:49 AM